FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Procedure Shows Promise for Sustained Weight Loss After GLP-1 Therapy
Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.
The Independent Pharmacist Championing Innovative, Patient-Centric Care
Amid the continuously evolving role of pharmacists in today’s health care landscape, independent owners like Amina Abubakar, PharmD, AAHIVP, are advancing the profession through innovation.
$0 Copay Program Effectively Improved Glycemic Control | ADA 2025
Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.
The Potential Impact Pharmaceutical Tariffs May Have on Pharmacies
Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.
Pharmacist Outreach Can Help Reduce Hypoglycemia Risk | ADA 2025
Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.
Telemedicine With GLP-1 Behavior Program Shows Significant Declines in Weight, Blood Pressure | ADA 2025
In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.